Detalhe da pesquisa
1.
Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations.
BMC Cancer
; 20(1): 83, 2020 Jan 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-32005111
2.
Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer.
Mod Pathol
; 31(6): 947-955, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29410488
3.
Bevacizumab beyond disease progression for advanced non-small cell lung cancer: Does persistence have its rewards?
Cancer
; 122(7): 1047-9, 2016 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26828851
4.
Genotype-Specific Differences in Circulating Tumor DNA Levels in Advanced NSCLC.
J Thorac Oncol
; 16(4): 601-609, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33388476
5.
Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations.
J Thorac Oncol
; 15(10): 1611-1623, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32540409
6.
Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC.
J Thorac Oncol
; 15(9): 1449-1459, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32389639
7.
The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma.
Clin Cancer Res
; 26(4): 892-901, 2020 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31694833
8.
Targeted Tissue and Cell-Free Tumor DNA Sequencing of Advanced Lung Squamous-Cell Carcinoma Reveals Clinically Significant Prevalence of Actionable Alterations.
Clin Lung Cancer
; 20(1): 30-36.e3, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30279110
9.
Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non-small-cell Lung Cancer (NSCLC).
Clin Lung Cancer
; 20(1): 43-47, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30343004
10.
PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer.
J Thorac Oncol
; 14(6): 1021-1031, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30780001
11.
Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy.
Cancers (Basel)
; 11(5)2019 May 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-31137625
12.
Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer.
Lung Cancer
; 112: 90-95, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29191606